CNSY
What one share of Cerenome holds
Surgical and Medical Instruments and Apparatus
Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (“CNS”) cancers. CNSide Diagnostics, LLC (“CNSide Diagnostics”) is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.
Cerenome’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.70 |
|---|---|
| Profit | −$4.34 |
| Capex (buildings and equipment) | $0.23 |
| Free cash flow | −$3.92 |
| Cash and investments | $0.32 |
| Book value | $0.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$697.94 | — | −$714.29 | — | $168.41 |
| 2021 | — | −$415.63 | — | −$318.88 | — | $261.99 |
| 2022 | — | −$289.58 | — | −$185.28 | — | $71.93 |
| 2023 | $39.10 | −$105.99 | $1.27 | −$103.56 | — | −$7.58 |
| 2024 | $18.91 | −$58.52 | $0.47 | −$34.74 | — | −$37.94 |
| 2025 | $1.68 | −$7.19 | $0.02 | −$6.70 | — | $0.72 |